Search
for
Sort by
Research 211–240 of 1000+
- SYSTEMATIC REVIEW OF ORAL JANUS KINASE INHIBITORS IN ALOPECIA AREATA: INSIGHTS FROM 2020 TO 2025 STUDIES
- Ritlecitinib in Alopecia Areata: A 24‐Week Real‐World Experience Contrasting JAK Inhibitor‐Naïve and JAK Inhibitor‐Experienced Patients
- APECED: JAK Inhibition in an Adult Case with Long-Term Follow-up
- A CASE STUDY OF LEECH THERAPY (JALAUKAVCHARAN) IN KHALITYA W. S. R. ALOPECIA AREATA
- A CASE STUDY OF LEECH THERAPY (JALAUKAVCHARAN) IN KHALITYA W. S. R. ALOPECIA AREATA
- Comparative Efficacy Evaluation of Alopecia Areata Management with Janus Kinase Inhibitors in Children: Retrospective Cohort Study
- 455 Beyond Immunity: TEC and JAK3 Kinase Activation in Melanocytes Drives Inflammation in Vitiligo
- 448 Combined therapeutic approach: Inhibition of MMP-9 and JAK Signaling Synergistically Prevents Depigmentation in Experimental Vitiligo
- Down‐regulation of Shh in the hair follicles of mice during chemotherapy‐induced hair loss is mediated by the JAK / STAT1 signaling pathway
- When JAK inhibitors are off the table: durable remission of severe alopecia areata with dexamethasone oral mini-pulse and a focused review
- Association of Janus kinase inhibitors with reduced depression in alopecia areata
- Real-World Effectiveness of JAK Inhibitors for Alopecia Totalis and Alopecia Universalis: A Single-Center Experience
- JAK Inhibitor Therapy in Alopecia Areata with Latent Hepatitis B Virus or Tuberculosis Infection: A Safety Assessment
- JAK Inhibitor Therapy in Alopecia Areata with Latent Hepatitis B Virus or Tuberculosis Infection: A Safety Assessment
- JAK1 Signaling Is Involved in the Induction of Mechanical Alloknesis in Atopic Dermatitis
- Environmental Modulation of JAK3-Mediated Immune Dysregulation in Alopecia Areata
- Kaempferol enhances hair growth by regulating JAK3/STAT6 and TGF-β/Smad signaling in human dermal papilla cells and a C57BL/6 mousemodel
- Comparative efficacy of Janus kinase inhibitors in severe alopecia areata: a network meta-analysis based on randomized controlled trials
- “<i>Nomen Omen</i>: The Myth of God Janus”
- JAK Family Expression and Therapeutic Implications in Primary Cicatricial Alopecias
- Determination of 13 janus kinase inhibitors in anti-alopecia cosmetics by ultra-high performance liquid chromatography-tandem triple quadrupole composite linear ion trap mass spectrometry
- JAK Inhibitors in Down Syndrome: Alopecia Areata Resolution and Vitiligo Improvement with Baricitinib
- 62202 Network meta-analysis (NMA) of FDA-approved JAK inhibitors for alopecia areata (AA) with at least 50% hair loss per SALT score
- 63418 JAK3/TEC kinase pathways are active in alopecia areata lesions, and their inhibition with Ritlecitinib prevents αCD3/αCD28+IL-2 induced immune privilege collapse in healthy hair follicles ex vivo
- Treatment of alopecia areata with JAK inhibitors
- 63407 A Descriptive Analysis of Patients With Moderate-to-Severe Atopic Dermatitis and Comorbid Alopecia Areata in the Abrocitinib JADE Clinical Program
- EFFECT OF JALAUKAVACHARANA IN KHALITYA (HAIRFALL): A CASE REPORT
- Discontinuation and restart of Janus kinase inhibitors due to pregnancy in alopecia areata: a case series
- Evaluating Current and Emergent JAK Inhibitors for Alopecia Areata: A Narrative Review
- Criteria for Commencing and Continuing Subsidised Janus Kinase Inhibitor Therapy in Australian Alopecia Areata Patients—Results From an Australian Expert Consensus Exercise